All In Biotech

Drug Trial Radar · NCT07311993

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients With Relapsed or Refractory Triple Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 5, 2025

Primary completion

Feb 2028

Study completion Jul 2029

Sponsor

Lead sponsor
Cellectar Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Dec 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and efficacy of 3 different dose levels of CLR 125 in patients with advanced triple negative breast cancer. The main questions the study aims to answer are: * What dose and regimen should be used in future trials of CLR 125 in patients with advanced triple negative breast cancer. * What side effects do participants have when taking CLR 125. Participants will: * Have CLR 125 administered via infusion 4 times each cycle; repeated every 8 weeks. * Visit the clinic once every 3 weeks for checkups and testing. * Report any side effects or new medications. Some participants may also receive one dose of CLR 131 to evaluate the amount of radiation delivered to various organs and to the tumor. These participants will: * Have 4 scans completed over 2 weeks * Have blood drawn 6 times over 2 weeks.

Conditions

  • Breast Cancer

Interventions

  • Iopofosine I 131Drug

    Investigational radiopharmaceutical product intended for IV administration.

  • CLR 125Drug

    Investigational radiopharmaceutical product intended for IV administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Determination for CLR 125Time frame: 57 days after initiation of last cycle (each cycle is 57 days)
  2. Number of adverse events related to study treatment (CLR 125)Time frame: Assessed throughout the study through 1 year following completion of treatment.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • United Theranostics

    Glen Burnie, Maryland · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • United Theranostics

    Princeton, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.